Last updated on April 2019

Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure


Brief description of study

The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared with placebo, on heart failure disease-specific biomarkers, symptoms, health status, and quality of life in patients with chronic heart failure with reduced systolic function.

Detailed Study Description

A 12-week randomized, double-blind, placebo-controlled trial to evaluate the effects of once-daily dapagliflozin 10 mg on heart failure disease-specific biomarkers (BNP and NTproBNP), symptoms, health status, and quality of life in patients with chronic heart failure with reduced systolic function.

Clinical Study Identifier: NCT02653482

Contact Investigators or Research Sites near you

Start Over

Saint Luke's Hospital of Kansas City

Kansas City, MO United States
6.62miles

Truman Medical Center

Kansas City, MO United States
8.34miles

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.